title: Clinicopathologic subtypes and compromise of lymph nodes in patients with breast cancer.
abstract: Breast cancer (BC) is currently a heterogeneous disease with variations in clinical behaviour. Classification according to subtypes has allowed progress in the individualisation of treatment. The objective of this study is to evaluate the risk of axillary node compromise in patients with BC, according to clinicopathologic subtypes. Materials and methods are a retrospective, descriptive-analytical study. All patients that had undergone surgery for invasive BC were included, with the study of sentinel lymph nodes (SLNs) at Hospital Clínico de la Pontificia Universidad Católica, between May 1999 and December 2012. The results showed 632 patients fulfilled the inclusion criteria, with the median age being 55 years (range: 28-95), and 559 (88.4%) patients presented with estrogen receptor and/or progesterone receptor positive tumours. Luminal A: 246 patients (38.9%), luminal B: 243 (38.4%), luminal not otherwise specified: 70 (11.1%) triple negative (TN): 60 (9.5%) and over expression of epidermal growth factor type 2 receptor (HER2 positive): 13 (2.1%). Luminal tumours displayed a greater risk of metastasis in the SLNs, but this difference was not statistically significant (p = 0.67). TN and HER2 positive tumours presented the greatest proportion of metastatic compromise in non-sentinel lymph nodes (non-SLNs) (57.1% and 50%, respectively). The presence of macrometastasis (MAM) in the SLN was associated with a greater risk of compromise of the non-SLN.
  
  
  CONCLUSIONS
  Luminal tumours are the most frequent and present a greater proportion of axillary lymph node compromise, without being statistically significant. TN and HER2 positive tumours tend to have a higher axillary compromise; however, this was not statistically significant in either. Only the presence of MAM in SLNs displayed a statistically significantly association in the compromise of non-SLNs.
authors.affiliation: Department of Oncologic and Maxillofacial Surgery, Pontificia Universidad Católica de Chile, Marcoleta 352, Santiago 8330033, Chile.
authors.forename: B
authors.initials: B
authors.lastname: Jaime Jans
authors.affiliation: Department of Oncologic and Maxillofacial Surgery, Pontificia Universidad Católica de Chile, Marcoleta 352, Santiago 8330033, Chile.
authors.forename: M
authors.initials: M
authors.lastname: Nicolás Escudero
authors.affiliation: Department of Oncologic and Maxillofacial Surgery, Pontificia Universidad Católica de Chile, Marcoleta 352, Santiago 8330033, Chile.
authors.forename: B
authors.initials: B
authors.lastname: Dahiana Pulgar
authors.affiliation: Department of Haematology-Oncology, Pontificia Universidad Católica de Chile, Marcoleta 352, Santiago 8330033, Chile.
authors.forename: C
authors.initials: C
authors.lastname: Francisco Acevedo
authors.affiliation: Department of Haematology-Oncology, Pontificia Universidad Católica de Chile, Marcoleta 352, Santiago 8330033, Chile.
authors.forename: R
authors.initials: R
authors.lastname: César Sánchez
authors.affiliation: Department of Oncologic and Maxillofacial Surgery, Pontificia Universidad Católica de Chile, Marcoleta 352, Santiago 8330033, Chile.
authors.forename: A Mauricio
authors.initials: AM
authors.lastname: Camus
keywords: breast neoplasms; lymph node dissection; sentinel lymph node biopsy; triple-negative breast neoplasms
references.citation: Oncol Rep. 2011 Apr;25(4):1063-71
references.pmid: 21258771
references.citation: J Clin Oncol. 2007 Aug 20;25(24):3670-9
references.pmid: 17664461
references.citation: Breast Cancer Res Treat. 2013 Jul;140(1):63-71
references.pmid: 23828499
references.citation: Cancer. 1999 Oct 15;86(8):1511-9
references.pmid: 10526280
references.citation: Ann Oncol. 2011 Aug;22(8):1736-47
references.pmid: 21709140
references.citation: Clin Breast Cancer. 2008 Jun;8(3):249-56
references.pmid: 18650155
references.citation: Rev Med Chil. 2014 Apr;142(4):428-35
references.pmid: 25117032
references.citation: N Engl J Med. 1998 Oct 1;339(14):941-6
references.pmid: 9753708
references.citation: Am J Surg. 2002 Jan;183(1):23-7
references.pmid: 11869698
references.citation: Ann Surg. 1999 Apr;229(4):536-41
references.pmid: 10203087
references.citation: Cancer. 2000 Feb 1;88(3):608-14
references.pmid: 10649254
references.citation: Lancet. 1998 Sep 19;352(9132):930-42
references.pmid: 9752815
references.citation: Eur J Surg Oncol. 2012 Dec;38(12):1211-7
references.pmid: 22954526
references.citation: Cancer. 2005 Feb 1;103(3):492-500
references.pmid: 15612028
references.citation: JAMA. 2011 Feb 9;305(6):569-75
references.pmid: 21304082
references.citation: Br J Surg. 2008 Mar;95(3):302-9
references.pmid: 17876750
references.citation: Ann Oncol. 2013 Sep;24(9):2206-23
references.pmid: 23917950
references.citation: Breast Cancer Res. 2010;12(4):207
references.pmid: 20804570
references.citation: CA Cancer J Clin. 2012 Jan-Feb;62(1):10-29
references.pmid: 22237781
references.citation: J Clin Oncol. 2014 May 1;32(13):1365-83
references.pmid: 24663048
references.citation: Maturitas. 2011 May;69(1):7-10
references.pmid: 21411254
references.citation: Nature. 2000 Aug 17;406(6797):747-52
references.pmid: 10963602
references.citation: J Clin Oncol. 2011 Nov 10;29(32):4273-8
references.pmid: 21990413
references.citation: Cancer. 2003 Dec 1;98(11):2307-15
references.pmid: 14635063
references.citation: Ann Surg Oncol. 2003 Dec;10(10):1140-51
references.pmid: 14654469
references.citation: J Natl Cancer Inst. 2003 Oct 15;95(20):1514-21
references.pmid: 14559873
references.citation: Cancer. 2002 May 15;94(10):2542-51
references.pmid: 12173319
references.citation: J Am Coll Surg. 2009 Feb;208(2):229-35
references.pmid: 19228534
references.citation: N Engl J Med. 2003 Aug 7;349(6):546-53
references.pmid: 12904519
references.citation: Breast Cancer Res Treat. 2008 Mar;108(2):191-201
references.pmid: 18297396
references.citation: Am Surg. 2003 Mar;69(3):209-11; discussion 212
references.pmid: 12678476
references.citation: JAMA. 2013 Oct 2;310(13):1385-94
references.pmid: 24084924
references.citation: Ann Surg Oncol. 2002 Oct;9(8):745-53
references.pmid: 12374657